Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of EDG-15400 in Healthy Adults
Sponsor: Edgewise Therapeutics, Inc.
Summary
The purposes of this Phase 1 study of EDG-15400 are to: 1. Learn about the safety of EDG-15400 after single and multiple doses in healthy adults 2. Learn about how EDG-15400 is tolerated after single and multiples doses in healthy adults 3. Evaluate the amount of EDG-15400 in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-15400 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-15400 in the blood is similar for the suspension and tablet forms of EDG-15400 in healthy adults Participants will receive a single or multiple doses of EDG-15400 or a placebo by mouth.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 59 Years
Study Type
INTERVENTIONAL
Enrollment
108
Start Date
2025-08-20
Completion Date
2026-05
Last Updated
2025-09-16
Healthy Volunteers
Yes
Conditions
Interventions
EDG-15400
EDG-15400 is administered orally
Placebo
Placebo is administered orally
Locations (1)
Celerion, Inc.
Tempe, Arizona, United States